Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human ALK-1/ACVRL1-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
Endotoxin: |
Please contact us for more information. |
Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human ALK-1 at 4 Mu g/mL (100 Mu L/well) can bind Human ACVR2B with a linear range of 0.08-2.4 Mu g/mL. |
Gene Symbol: |
ACVRL1 |
Gene ID: |
94 |
Uniprot ID: |
ACVL1_HUMAN |
Immunogen: |
Recombinant Human ALK-1 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Asp22-Gln118) of human ALK-1 (Accession #NP_000011.2) fused with a 6×His tag at the C-terminus. |
Function | Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well. |
Protein Name | Serine/Threonine-Protein Kinase Receptor R3Skr3Activin Receptor-Like Kinase 1Alk-1Tgf-B Superfamily Receptor Type ITsr-I |
Database Links | Reactome: R-HSA-201451 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | Serine/Threonine-Protein Kinase Receptor R3 proteinSkr3 proteinActivin Receptor-Like Kinase 1 proteinAlk-1 proteinTgf-B Superfamily Receptor Type I proteinTsr-I proteinACVRL1 proteinACVRLK1 proteinALK1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance